ReShape Lifesciences (NASDAQ:RSLS) Shares to Reverse Split on Monday, September 23rd

ReShape Lifesciences Inc. (NASDAQ:RSLSFree Report) shares are set to reverse split before the market opens on Monday, September 23rd. The 1-58 reverse split was announced on Thursday, September 19th. The number of shares owned by shareholders will be adjusted after the closing bell on Friday, September 20th.

ReShape Lifesciences Trading Down 10.1 %

Shares of RSLS stock opened at $0.11 on Friday. ReShape Lifesciences has a 12-month low of $0.11 and a 12-month high of $0.67. The business’s 50 day moving average is $0.18 and its two-hundred day moving average is $0.18.

ReShape Lifesciences (NASDAQ:RSLSGet Free Report) last announced its earnings results on Wednesday, August 14th. The medical device company reported ($0.06) earnings per share for the quarter. ReShape Lifesciences had a negative return on equity of 208.37% and a negative net margin of 112.11%. The business had revenue of $1.97 million for the quarter.

Analyst Upgrades and Downgrades

Separately, Maxim Group reiterated a “hold” rating on shares of ReShape Lifesciences in a research report on Wednesday, July 17th.

View Our Latest Stock Report on ReShape Lifesciences

About ReShape Lifesciences

(Get Free Report)

ReShape Lifesciences Inc provides products and services that manages and treat obesity and metabolic diseases in the United States, Australia, Europe, and internationally. The company's product portfolio includes Lap-Band System, a minimally invasive long-term treatment of severe obesity and more invasive surgical stapling procedures, such as the gastric bypass or sleeve gastrectomy; Lap-Band 2.0 System, an adjustable postoperatively to increase or decrease the pressure to the band in order to optimize an individual's comfort and therapy effectiveness; and ReShape Calibration Tubes, that fits the lesser curvature of the stomach to reach the pylorus.

Read More

Receive News & Ratings for ReShape Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ReShape Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.